DAVA Oncology
@DAVAOnc
Followers
2K
Following
1K
Media
1K
Statuses
3K
DAVA Oncology is a strategic consulting company committed to delivering high quality oncology education and expanding access novel cancer therapies.
Dallas, TX
Joined July 2014
RT @LeXiuning: Thank you @DAVAOnc @vinayjai for another successful Lung Summit meeting! Nice to hangout and exchange scientific ideas in thā¦.
0
4
0
RT @lungoncdoc: Frolleauge (friend +colleague, yes still trying to make this happen š¤£) @christinemphmd breaks down how AI can help us betteā¦.
0
4
0
RT @Latinamd: #HawaiiLung25 Fascinating talks by Dr Jia Wu @MDAndersonNews on AI- augmented digital twin frameworks for clinical trial predā¦.
0
3
0
RT @Latinamd: #HawaiiLung25 @christinemphmd @WeillCornell presents on the possibilities of incorporating large real world data, NLP to imprā¦.
0
4
0
Dr. @DrJedDowell highlighted lung cancer precision oncology efforts in the VA, emphasizing expanded molecular testing through the NPOP. Ongoing work addresses disparities and aims to ensure equitable access to targeted therapies for veterans. #DAVALung
0
1
4
RT @Latinamd: #HawaiiLung25 Blown away by presentation by @DrJaimeLaurel @MGHCancerCenter on promise of #metabolomics - targeting metabolisā¦.
0
2
0
RT @christinemphmd: Love this delicious analogy for bispecific PD1+CTLA4 volrustomig for #mesothelioma by @Arohatgi at @DAVAOnc #HawaiiLungā¦.
0
1
0
RT @Latinamd: #HawaiiLung25 Back to back excellent presentations by @LoganRoofMD @OSUCCC_James and @Arohatgi @SitemanCenter on new therapieā¦.
0
2
0
Targeting ADAR1 may enhance tumor immunogenicity and overcome resistance to immune surveillance in lung cancer. Preclinical models show ADAR1 silencing reduces tumorigenicity and stemness, supporting combinations with ICIs. Dr. Robert Kratzke @UMNews shared ongoing efforts.
0
0
1
RT @Latinamd: #HawaiiLung25 The amazing @JulieBrahmer @HopkinsThoracic breaks down the role of the HIPPO š¦ pathway in #mesothelioma and rolā¦.
0
1
0
Dr. @DAielloMD discussed next-gen checkpoints in NSCLC, highlighting distinct expression patterns of HHLA2, B7-H3, and B7x. Findings support integrating RNA and protein profiling to refine immunotherapy biomarkers and guide treatment in molecular subtypes. #DAVALung
0
1
2
Starting Now: Cytokines and Emerging Checkpoint Strategies.Moderated by: Dr. Ramaswamy Govindan @washumedicine.#DAVALung
0
2
6
Dr. Leah Backhus from Stanford Medicine reviews evolving surgical strategies in pleural mesothelioma, emphasizing patient selection, multimodal therapy & HITHOC benefits post-resection at #DAVALung Summit. #Mesothelioma #ThoracicSurgery
0
1
3
Dr. Julie Brahmer from @JohnsHopkins delves into HIPPO/YAPāTEAD axis targeting with IAG933, a firstāināhuman TEAD inhibitor showing early antiātumor activity in mesothelioma & NSCLC #Mesothelioma #ImmunoOnc #DAVALung
0
3
15
Dr. Logan Roof from @OhioStateUniv highlights Volrustomig, a novel PD-1/CTLA-4 bispecific antibody, at #DAVALung Summit. Promising early data in NSCLC & pleural mesothelioma show improved T-cell activation, with trials now underway #Immunotherapy #Lungcancer
0
1
4
Discover how spatial transcriptomics is reshaping lung cancer pathology, Dr. Ming Tsao from @pmcancercentre highlights AI-integrated single-cell tech to decode lineage plasticity & histologic transformation #SpatialTranscriptomics #LungCancer #AIPathology #DAVALung
0
0
3
Dr. Jaime Schneider from @MGHCancerCenter shares insights on lung cancer metabolic dependencies, highlighting MTAP-PRMT5 synthetic lethality, ALK-driven GUK1 regulation, and FAO-driven persisters, to inform precision metabolic therapies #CancerMetabolism #LungCancer #DAVALung
0
0
1
Starting Now: Genomics/Epigenomics/Proteomics/ Metabolomics .Moderated by: Dr. John Heymach @MDAndersonNews.#DAVALung
0
0
1